Loading
SGR-2921 is a small molecule from Schrödinger that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped.
SGR-2921 is a small molecule (oral) from Schrödinger. A CDC7 inhibitor. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome. ClinicalTrials.gov registers it in one study linked below. Discontinued in August 2025 per Schrödinger's 10-Q for the quarter to 30 June 2026; the phase 1 trial NCT05961839 is TERMINATED on the registry. Whether it works in people has not been established unless a trial below reports it.
A CDC7 inhibitor. Connects to CDC7.
1.SGR-2921 slips into a pocket on CDC7.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SGR-2921" OR ABSTRACT:"SGR-2921") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SGR-2921, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tags pipeline, discontinued.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Shares the tags pipeline, discontinued.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/